Neuroblastoma — Trials, FDA Actions & Pivotal Research

20 active Neuroblastoma trials currently recruiting in the US, sourced from ClinicalTrials.gov.

Synced daily from openFDA and ClinicalTrials.gov. Last sync: July 6, 2026.

Recruiting trials by city

Cities where Neuroblastoma trials in our archive had recruiting sites. Each link lists every currently recruiting paid clinical trial at that location.

Birmingham, AL Los Angeles, CA Boston, MA Gainesville, FL San Francisco, CA Aurora, CO Cincinnati, OH Columbus, OH Little Rock, AR Madison, WI Palo Alto, CA

Active Neuroblastoma trials

Currently recruiting US trials matching Neuroblastoma, sourced live from ClinicalTrials.gov. We’ll add per-event articles here as those trials post results or hit primary completion.

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

for Relapsed Neuroblastoma

1 location in Houston

Sponsor: Baylor College of Medicine

Sex: All·Age: 1 - 24

Code: NCT07211737·Phase 1·Not Yet Recruiting

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

for Neuroblastoma

13 locations incl. Los Angeles

Sponsor: New Approaches to Neuroblastoma Therapy Consortium

Sex: All·Age: 1 - 30

Code: NCT07261241·Phase 2·Not Yet Recruiting

Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma

for Neuroblastoma

1 location in Cincinnati

Sponsor: Children's Hospital Medical Center, Cincinnati

Sex: All·Age: 1 - 39

Code: NCT07635056·Phase 2·Recruiting

Apply to this trial

B7-H3.CD28Z.CART in Solid Tumors

for Pediatric Solid Tumor

1 location in Boston

Sponsor: Robbie Majzner

Sex: All·Age: 9 Months - 30

Code: NCT07358260·Phase 1·Not Yet Recruiting

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

for Neuroblastoma

Sponsor: Shenzhen Geno-Immune Medical Institute

Sex: All·Age: 1 - 65

Code: NCT04637503·Phase 1, Phase 2·Recruiting

Apply to this trial

Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5

for High-Risk Neuroblastoma

Sponsor: Shaare Zedek Medical Center

Sex: All·Age: 12 Months - 21

Code: NCT07537400·Phase 2·Not Yet Recruiting

Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors

for Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

Sponsor: Sun Yat-sen University

Sex: All·Age: 2 - 18

Code: NCT07584499·Phase 1·Recruiting

Apply to this trial

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

for Atypical Teratoid/Rhabdoid Tumor

12 locations incl. Birmingham

Sponsor: Milton S. Hershey Medical Center

Sex: All·Age: Up to 26

Code: NCT06465199·Phase 1, Phase 2·Recruiting

Apply to this trial

Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma

for Leukaemia (Acute Lymphoblastic)

Sponsor: Michel Duval

Sex: All·Age: 2 - 12

Code: NCT07518654·Phase 1·Not Yet Recruiting

A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

for High-Risk Neuroblastoma

5 locations incl. Aurora

Sponsor: Renaissance Pharma Ltd.

Sex: All·Age: 18 Months - 18

Code: NCT07549321·Phase 2, Phase 3·Recruiting

Apply to this trial

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

for Relapsed Neuroblastoma

Sponsor: Beijing Biotech

Sex: All·Age: 12 Months - 21

Code: NCT07502287·Phase 1, Phase 2·Recruiting

Apply to this trial

Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma.

for Neuroblastoma

Sponsor: Institut Curie

Sex: All·Age: 365 Days - 17

Code: NCT07111117·Phase 2·Not Yet Recruiting

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

for Neuroblastoma

1 location in Gainesville

Sponsor: University of Florida

Sex: All·Age: 6 Months - 25

Code: NCT06625190·Phase 1, Phase 2·Recruiting

Apply to this trial

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

for Rhabdomyosarcoma

2 locations incl. Washington D.C.

Sponsor: Children's National Research Institute

Sex: All·Age: 1 - 23

Code: NCT07172958·Phase 1·Recruiting

Apply to this trial

An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma

for Neuroblastoma

Sponsor: Princess Maxima Center for Pediatric Oncology

Sex: All·Age: 1 - 18

Code: NCT07399821·Phase 1, Phase 2·Recruiting

Apply to this trial

Interest of Preoperative Arteriography to Identify the Adamkiewicz Artery Before Surgery for Basi-thoracic Neuroblastic Tumors

for Tumor, Solid

Sponsor: Assistance Publique - Hôpitaux de Paris

Sex: All·Age: Up to 18

Code: NCT06798532·Not Yet Recruiting

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

for Neuroblastoma

1 location in Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 3 - 35

Code: NCT06995872·Phase 1·Recruiting

Apply to this trial

Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region.

for Dementia

Sponsor: prof. dr. Koen Van Laere

Sex: All·Age: 28 Days+·Accepts healthy volunteers

Code: NCT07595666·Enrolling By Invitation

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

for CNS Embryonal Tumor

Sponsor: C17 Council

Sex: All·Age: Up to 6

Code: NCT06942039·EARLY_Phase 1·Recruiting

Apply to this trial

GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.

for Neuroblastoma

Sponsor: Chinese PLA General Hospital

Sex: All·Age: 6 - 12

Code: NCT07090538·EARLY_Phase 1·Not Yet Recruiting